Eton Pharmaceuticals (ETON) Cost of Revenue (2019 - 2025)
Eton Pharmaceuticals' Cost of Revenue history spans 7 years, with the latest figure at $8.2 million for Q4 2025.
- On a quarterly basis, Cost of Revenue rose 58.21% to $8.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $30.5 million, a 95.28% increase, with the full-year FY2025 number at $37.2 million, up 138.53% from a year prior.
- Cost of Revenue hit $8.2 million in Q4 2025 for Eton Pharmaceuticals, down from $14.6 million in the prior quarter.
- Over the last five years, Cost of Revenue for ETON hit a ceiling of $14.6 million in Q3 2025 and a floor of $174000.0 in Q2 2021.
- Historically, Cost of Revenue has averaged $3.3 million across 5 years, with a median of $2.5 million in 2023.
- Biggest five-year swings in Cost of Revenue: soared 1477.59% in 2022 and later plummeted 77.19% in 2025.
- Tracing ETON's Cost of Revenue over 5 years: stood at $372000.0 in 2021, then skyrocketed by 474.73% to $2.1 million in 2022, then surged by 72.26% to $3.7 million in 2023, then surged by 40.4% to $5.2 million in 2024, then skyrocketed by 58.21% to $8.2 million in 2025.
- Business Quant data shows Cost of Revenue for ETON at $8.2 million in Q4 2025, $14.6 million in Q3 2025, and $7.0 million in Q2 2025.